Prophage exotoxins enhance colonization fitness in epidemic scarlet fever-causing Streptococcus pyogenes

The re-emergence of scarlet fever poses a new global public health threat. The capacity of North-East Asian serotype M12 (emm12) Streptococcus pyogenes (group A Streptococcus, GAS) to cause scarlet fever has been linked epidemiologically to the presence of novel prophages, including prophage ΦHKU.vir encoding the secreted superantigens SSA and SpeC and the DNase Spd1. Here we report the comprehensive molecular characterization of ΦHKU.vir-encoded exotoxins. We demonstrate that streptolysin O (SLO)-induced glutathione efflux from host cellular stores is a previously unappreciated GAS virulence mechanism that promotes SSA release and activity, representing the first description of a thiol-activated bacterial superantigen. Spd1 is required for optimal growth in human blood, confers resistance to neutrophil killing, and degrades neutrophil extracellular traps (NETs). Investigating single, double and triple isogenic knockout mutants of the ΦHKU.vir-encoded exotoxins, we find that SpeC and Spd1 act synergistically to facilitate nasopharyngeal colonization in a mouse model. These results offer insight into the etiology and pathogenesis of scarlet fever-causing GAS mediated by phage ΦHKU.vir exotoxins.

[1]  Stephan Brouwer,et al.  Genetic Manipulation of Group A Streptococcus-Gene Deletion by Allelic Replacement. , 2020, Methods in molecular biology.

[2]  W. Demczuk,et al.  Identification of Streptococcus pyogenes M1UK clone in Canada. , 2019, The Lancet. Infectious diseases.

[3]  J. Parkhill,et al.  Emergence of dominant toxigenic M1T1 Streptococcus pyogenes clone during increased scarlet fever activity in England: a population-based molecular epidemiological study , 2019, The Lancet. Infectious diseases.

[4]  V. Nizet,et al.  Detection of epidemic scarlet fever group A Streptococcus in Australia. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  J. Lacey,et al.  Scarlet fever changes its spots. , 2019, The Lancet. Infectious diseases.

[6]  L. McGee,et al.  Emergent Invasive Group A Streptococcus dysgalactiae subsp. equisimilis, United States, 2015–2018 , 2019, Emerging infectious diseases.

[7]  Y. Gan,et al.  Modulation of bacterial virulence and fitness by host glutathione. , 2019, Current opinion in microbiology.

[8]  C. Yung,et al.  A 12 year outbreak of scarlet fever in Singapore. , 2018, The Lancet. Infectious diseases.

[9]  Michelle L. Reniere.  Reduce, Induce, Thrive: Bacterial Redox Sensing during Pathogenesis , 2018, Journal of bacteriology.

[10]  T. Chan,et al.  Resurgence of scarlet fever in China: a 13-year population-based surveillance study , 2018, The Lancet Infectious Diseases.

[11]  N. West,et al.  Endopeptidase PepO Regulates the SpeB Cysteine Protease and Is Essential for the Virulence of Invasive M1T1 Streptococcus pyogenes , 2018, Journal of bacteriology.

[12]  M. Davies,et al.  Scarlet Fever Epidemic in China Caused by Streptococcus pyogenes Serotype M12: Epidemiologic and Molecular Analysis , 2018, EBioMedicine.

[13]  V. Saliba,et al.  Resurgence of scarlet fever in England, 2014-16: a population-based surveillance study. , 2017, The Lancet. Infectious diseases.

[14]  Stephan Brouwer,et al.  Scarlet fever makes a comeback. , 2017, The Lancet. Infectious diseases.

[15]  S. Haeryfar,et al.  Nasopharyngeal infection by Streptococcus pyogenes requires superantigen-responsive Vβ-specific T cells , 2017, Proceedings of the National Academy of Sciences.

[16]  Ken Smith,et al.  Enhanced nasopharyngeal infection and shedding associated with an epidemic lineage of emm3 group A Streptococcus , 2017, Virulence.

[17]  Sun-Hee Kim,et al.  Incidence and Characteristics of Scarlet Fever, South Korea, 2008–2015 , 2017, Emerging infectious diseases.

[18]  R. Guy,et al.  Genome analysis following a national increase in Scarlet Fever in England 2014 , 2017, BMC Genomics.

[19]  R. Olsen,et al.  Contribution of Secreted NADase and Streptolysin O to the Pathogenesis of Epidemic Serotype M1 Streptococcus pyogenes Infections. , 2017, The American journal of pathology.

[20]  V. Nizet,et al.  Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models , 2016, mBio.

[21]  D. Bessen.  Tissue tropisms in group A Streptococcus: what virulence factors distinguish pharyngitis from impetigo strains? , 2016, Current opinion in infectious diseases.

[22]  A. Efstratiou,et al.  Scarlet Fever Upsurge in England and Molecular-Genetic Analysis in North-West London, 2014 , 2016, Emerging infectious diseases.

[23]  V. Fischetti,et al.  Streptococcus pyogenes: Basic Biology to Clinical Manifestations [Internet] , 2016 .

[24]  Stevens Dl,et al.  Streptococcus pyogenes: Basic Biology to Clinical Manifestations , 2016 .

[25]  V. Nizet,et al.  Streptolysin O Rapidly Impairs Neutrophil Oxidative Burst and Antibacterial Responses to Group A Streptococcus , 2015, Front. Immunol..

[26]  Ruifu Yang,et al.  Transfer of scarlet fever-associated elements into the group A Streptococcus M1T1 clone , 2015, Scientific Reports.

[27]  G. Dougan,et al.  Emergence of scarlet fever Streptococcus pyogenes emm12 clones in Hong Kong is associated with toxin acquisition and multidrug resistance , 2014, Nature Genetics.

[28]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[29]  S. Haeryfar,et al.  Bacterial Superantigens Promote Acute Nasopharyngeal Infection by Streptococcus pyogenes in a Human MHC Class II-Dependent Manner , 2014, PLoS pathogens.

[30]  João André Carriço,et al.  Scarlet Fever Is Caused By a Limited Number of Streptococcus pyogenes Lineages and Is Associated with the Exotoxin Genes ssa, speA and speC , 2014, The Pediatric infectious disease journal.

[31]  T. Proft,et al.  Toxin–antitoxin-stabilized reporter plasmids for biophotonic imaging of Group A streptococcus , 2013, Applied Microbiology and Biotechnology.

[32]  V. Nizet,et al.  Plasmin(ogen) Acquisition by Group A Streptococcus Protects against C3b-Mediated Neutrophil Killing , 2013, Journal of Innate Immunity.

[33]  S. Cui,et al.  Characteristics of Group A Streptococcus Strains Circulating during Scarlet Fever Epidemic, Beijing, China, 2011 , 2013, Emerging infectious diseases.

[34]  Svein Gjelstad,et al.  Are children carrying the burden of broad-spectrum antibiotics in general practice? Prescription pattern for paediatric outpatients with respiratory tract infections in Norway , 2013, BMJ Open.

[35]  T. Tsang,et al.  Scarlet Fever Epidemic, Hong Kong, 2011 , 2012, Emerging infectious diseases.

[36]  E. Lau,et al.  Scarlet Fever Outbreak, Hong Kong, 2011 , 2012, Emerging infectious diseases.

[37]  Xiaohong Wang,et al.  Outbreak of Scarlet Fever Associated With emm12 Type Group A Streptococcus in 2011 in Shanghai, China , 2012, The Pediatric infectious disease journal.

[38]  S. Lok,et al.  Molecular characterization of the 2011 Hong Kong scarlet fever outbreak. , 2012, The Journal of infectious diseases.

[39]  J. Turkenburg,et al.  The structural characterization of a prophage-encoded extracellular DNase from Streptococcus pyogenes , 2011, Nucleic acids research.

[40]  T. Tsang,et al.  Scarlet Fever Epidemic , 2012 .

[41]  Yhu-Chering Huang,et al.  Scarlet fever outbreak in Hong Kong, 2011. , 2011, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[42]  J. Beckwith,et al.  Laboratory evolution of glutathione biosynthesis reveals natural compensatory pathways. , 2011, Nature chemical biology.

[43]  A. Khoruts,et al.  Induction of TGF-β1 and TGF-β1–dependent predominant Th17 differentiation by group A streptococcal infection , 2010, Proceedings of the National Academy of Sciences.

[44]  A. Fauci,et al.  The challenge of emerging and re-emerging infectious diseases , 2010, Nature.

[45]  P. Schlievert,et al.  Cytolysins Augment Superantigen Penetration of Stratified Mucosa1 , 2009, The Journal of Immunology.

[46]  V. Nizet,et al.  Streptolysin O Promotes Group A Streptococcus Immune Evasion by Accelerated Macrophage Apoptosis* , 2009, Journal of Biological Chemistry.

[47]  J. Carapetis,et al.  Superantigen genes in group A streptococcal isolates and their relationship with emm types. , 2008, Journal of medical microbiology.

[48]  L. Gillam,et al.  Consent in paediatric research: an evaluation of the guidance provided in the 2007 NHMRC National statement on ethical conduct in human research , 2008, The Medical journal of Australia.

[49]  A. Kwon,et al.  Translational Attenuation and mRNA Stabilization as Mechanisms of erm(B) Induction by Erythromycin , 2008, Antimicrobial Agents and Chemotherapy.

[50]  Malak Kotb,et al.  DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection , 2007, Nature Medicine.

[51]  B. Moza,et al.  Molecular Basis of TCR Selectivity, Cross-Reactivity, and Allelic Discrimination by a Bacterial Superantigen: Integrative Functional and Energetic Mapping of the SpeC-Vβ2.1 Molecular Interface1 , 2006, The Journal of Immunology.

[52]  T. Proft,et al.  Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[53]  W. Alexander,et al.  Humanized transgenic mice expressing HLA DR4-DQ3 haplotype: reconstitution of phenotype and HLA-restricted T-cell responses. , 2006, Tissue antigens.

[54]  Ramy K. Aziz,et al.  DNase Expression Allows the Pathogen Group A Streptococcus to Escape Killing in Neutrophil Extracellular Traps , 2006, Current Biology.

[55]  R. Tweten,et al.  Cholesterol-Dependent Cytolysins, a Family of Versatile Pore-Forming Toxins , 2005, Infection and Immunity.

[56]  J. Musser,et al.  Evolutionary origin and emergence of a highly successful clone of serotype M1 group a Streptococcus involved multiple horizontal gene transfer events. , 2005, The Journal of infectious diseases.

[57]  M. Wessels,et al.  Extracellular group A Streptococcus induces keratinocyte apoptosis by dysregulating calcium signalling , 2005, Cellular microbiology.

[58]  R. Edwards,et al.  Mosaic Prophages with Horizontally Acquired Genes Account for the Emergence and Diversification of the Globally Disseminated M1T1 Clone of Streptococcus pyogenes , 2005, Journal of bacteriology.

[59]  M. Jenkins,et al.  Primary induction of CD4 T cell responses in nasal associated lymphoid tissue during group A streptococcal infection , 2004, European journal of immunology.

[60]  A. Llera,et al.  Cloning, expression and interaction of human T-cell receptors with the bacterial superantigen SSA. , 2004, European journal of biochemistry.

[61]  A. Fauci,et al.  The challenge of emerging and re-emerging infectious diseases , 2004, Nature.

[62]  A. Zychlinsky,et al.  Neutrophil Extracellular Traps Kill Bacteria , 2004, Science.

[63]  M. Caparon,et al.  Contribution of Glutathione Peroxidase to the Virulence of Streptococcus pyogenes , 2004, Infection and Immunity.

[64]  James M. Musser,et al.  Prophage Induction and Expression of Prophage-EncodedVirulence Factors in Group A Streptococcus Serotype M3 StrainMGAS315 , 2003, Infection and Immunity.

[65]  V. Fischetti,et al.  The In Vitro Interaction of Streptococcus pyogenes with Human Pharyngeal Cells Induces a Phage-Encoded Extracellular DNase , 2002, Infection and Immunity.

[66]  Hongmin Li,et al.  Structures of two streptococcal superantigens bound to TCR beta chains reveal diversity in the architecture of T cell signaling complexes. , 2002, Structure.

[67]  J. Roberts,et al.  Acute pharyngitis. , 2020, The New England journal of medicine.

[68]  M. Palmer,et al.  The family of thiol-activated, cholesterol-binding cytolysins. , 2001, Toxicon : official journal of the International Society on Toxinology.

[69]  V. Arcus,et al.  Immunological and Biochemical Characterization of Streptococcal Pyrogenic Exotoxins I and J (SPE-I and SPE-J) from Streptococcus pyogenes1 , 2001, The Journal of Immunology.

[70]  Don C. Wiley,et al.  Structure of a human insulin peptide–HLA-DQ8 complex and susceptibility to type 1 diabetes , 2001, Nature Immunology.

[71]  Freya Q. Schafer,et al.  Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. , 2001, Free radical biology & medicine.

[72]  V. Fischetti,et al.  Induction of Lysogenic Bacteriophage and Phage-Associated Toxin from Group A Streptococci during Coculture with Human Pharyngeal Cells , 2001, Infection and Immunity.

[73]  A. Bisno,et al.  Acute pharyngitis. , 2001, The New England journal of medicine.

[74]  T. Jardetzky,et al.  Structural basis for HLA–DQ binding by the streptococcal superantigen SSA , 1999, Nature Structural Biology.

[75]  T. Proft,et al.  Identification and Characterization of Novel Superantigens from Streptococcus pyogenes , 1999, The Journal of experimental medicine.

[76]  T. Yutsudo,et al.  Serologic Evidence That Streptococcal Superantigens Are Not Involved in the Pathogenesis of Kawasaki Disease , 1997, Microbiology and immunology.

[77]  J. Fraser,et al.  The Superantigen Streptococcal Pyrogenic Exotoxin C (SPE-C) Exhibits a Novel Mode of Action , 1997, The Journal of experimental medicine.

[78]  R. Kaul,et al.  Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. , 1996, Journal of immunology.

[79]  Don C. Wiley,et al.  Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen , 1994, Nature.

[80]  D. Morens,et al.  Severe streptococcal infections in historical perspective. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[81]  D. Botstein,et al.  Host/vector interactions which affect the viability of recombinant phage lambda clones. , 1986, Gene.

[82]  J. Alouf,et al.  Streptococcal toxins (streptolysin O, streptolysin S, erythrogenic toxin). , 1980, Pharmacology & therapeutics.